Treatments, especially for NUT carcinoma, have been undergoing development during the last decades; however, these drugs mostly target genes fused to NUTM1 in cancer; for example, BET inhibitors target BRD4 in the BRD4-NUTM1 fusion protein. The gene discussed is NUTM1; the disease is nut midline carcinoma.